Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2018-08-31
- Target Recruit Count
- 142
- Registration Number
- NCT00134017
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 14
- Registration Number
- NCT00113919
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, United States
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00112645
- Locations
- 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00093587
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 2
- Registration Number
- NCT00092937
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse
- Conditions
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00002554
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00003661
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT00003662
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸University of Florida Health Science Center, Gainesville, Florida, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00002831
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-12-23
- Target Recruit Count
- 1520
- Registration Number
- NCT00002549
- Locations
- 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.